Antibody response after a booster dose of SARS-CoV-2 vaccine in liver transplant recipients and those with chronic liver diseases | Annals of Hepatology
Spike-antibody waning after second dose of BNT162b2 or ChAdOx1 - The Lancet
Antibody Response to the BA.5 Bivalent Vaccine Shot: a Two-Year Follow-Up Study following Initial COVID-19 mRNA Vaccination | Microbiology Spectrum
Strong SARS-CoV-2 Antibody Response After Booster Dose of BNT162b2 mRNA Vaccines in Uninfected Healthcare Workers
Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants | NEJM
Mix-and-match booster shots beneficial in boosting SARS-CoV-2 immunity
Should I get my COVID vaccine booster? Yes, it increases protection against COVID, including Omicron
COVID-19 antibodies appear to wane rapidly, so prepare for booster shots, study suggests – Orange County Register
The comparability of Anti-Spike SARS-CoV-2 antibody tests is time-dependent: a prospective observational study | medRxiv
Immune imprinting and SARS-CoV-2 vaccine design: Trends in Immunology
Moderna 2-strain booster shows strong subvariant antibody response | CIDRAP
Are COVID-19 vaccine boosters needed? | Virology Blog
COVID-19 Booster Increases Durability of Antibody Response
Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study - eClinicalMedicine
Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response | Annals of the Rheumatic Diseases
Prof. Akiko Iwasaki on X: "Why do we need a booster shots? This is because B cell responses induced by first dose only generates lower levels, lower affinity and short lived antibody
COVID-19 vaccine booster dose benefits patients with cancer
Antibody Response to Omicron BA.4–BA.5 Bivalent Booster | NEJM
Vaccines | Free Full-Text | The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What
Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint | medRxiv
Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study - The Lancet Microbe
Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222 - ScienceDirect
